Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
130 participants
OBSERVATIONAL
2006-02-28
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neural Mechanisms of Sensory Processing Anomalies
NCT06234033
Emotional and Change-related Attention in Autism
NCT02160119
Neurophysiological Molecular and Developmental Analysis of the Glutamate Synapse in Autism
NCT01770548
Brain Dynamics Involved in Generating Tics and Controlling Voluntary Movement
NCT00056420
Electrophysiological Signatures of Distinct Working Memory Subprocesses That Predict Long-term Memory Success
NCT05892419
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aim 1: To recruit 75 children with autism and 75 age- and sex-matched controls ages 6 to 8 years old for an electrophysiological study and to characterize the subjects using appropriate instruments for autism diagnosis, language functioning and behavior/sensory profile, and to measure head circumferences Aim 2: To acquire and analyze event-related potential (ERP) data in the auditory and visual modality.
ERP Hypothesis: Increased amplitude, altered morphology, impaired temporal discrimination and delayed responsiveness will be found early in the processing hierarchy, and the severity of these abnormalities will be associated with the severity of dysfunction at higher levels of cortical processing.
Aim 3: To acquire EEG data and to analyze it quantitatively. Quantitative EEG Hypothesis: Both interhemispheric and intrahemispheric coherence measures of the EEG will be significantly deviant from those in the normal sample and predicted by abnormalities of ERPs. In addition, EEG background alpha activity will show post mature (i.e. higher) frequencies (Hz) than would be expected for age and focal epileptiform activity and slowing (i.e. paroxysmal theta) will predict dysfunction on the ERPs.
Rationale:
The goal of this grant is to use electrophysiological measures to characterize abnormalities in gating and timing in the autistic brain. The motivation for this research project derives from findings and models in autism of increased excitation/inhibition ratios, increased brain and white matter volume and altered connectivity. These changes, alone and in combination, have the potential to alter the intensity, timing and integration of signaling at multiple stages of processing. These signaling problems can potentially lead to the autistic behavioral phenotype through cognitive processing abnormalities including the hyperspecificity/overselectivity of autism, as well as to such features of autism as sensory processing abnormalities, seizures, and anxiety. We believe that characterizing abnormalities related to gating and timing phenomena may lead to the development of an electrophysiological battery that can be utilized for early diagnosis, prognosis and subtyping of autism, as well as the tracking of treatment efficacy.
Subjects:
Subjects will be recruited from the general population, the Ladders Clinic at MGH/Spaulding Hospital, where the PI, Dr. Martien, is employed as a clinician, as well as from the clinical practice of Dr. Herbert at the MGH-Institute of Health Professions preschool clinic. Flyers will be placed on available bulletin boards at the two clinics and throughout the greater Boston area, particularly at all Partners, Harvard, MIT, hospital, clinic, research, and educational settings.
The study will seek to enroll eighty 75, 6 to 8 year olds with autism and 75 age and sex matched controls. Children will be considered for inclusion in the autism group if:
* English is the primary language in the home
* Experimental group: Child meets criteria for autism on the ADI-R and ADOS evaluation scales (this inclusion criteria will be explained during the consent process).
They meet non of the Exclusionary criteria, which include:
* Known genetic disorder
* Hearing or gross sensorimotor deficits
* Clinical evidence of progressive encephalopathy
* Asphyxia at birth or any other time
* Frequent seizures or use of anticonvulsant drugs or psychotropic medication
* Known presence of focal brain lesions, brain atrophy or ventriculomegaly. Children will be considered for the control group if the child meets all of the above criteria except they do not meet the criteria for autism or close to it on the ADOS and ADI-R evaluation scales.
Methods:
The child will be seated in a comfortable chair and the physiological assessment will begin after a head circumference is obtained with a tape measure, an EEG cap is placed on the child's head and gel is applied to each electrode in the cap. The tasks include 5 minutes of baseline EEG recording while the child is looking at a design on a monitor placed 2 meters in front of the chair. We then will proceed with a series of auditory and visual stimuli presented by computer through two speakers placed 1 meter in front of the child (auditory) and strobe (visual) at 50 cm. The paradigms will include a presentation of pairs of tones with variable interstimulus intervals presented in random order at 65 dB SPL, a paradigm with either 1000 Hz or 800 Hz at 65 dB, and a final auditory paradigm with two different phonemes, presented at 65 dB. The visual tasks will involve the presentation of flashes of light which vary in frequency and luminance both reflected off a white board one meter from the child and directly at the child's visual field. In each series, there will be a 1 minute break between two blocks of 100 trials each for a total of 200 trials. The experimenter will show the child an interesting toy and talk to the child during the break.
The parent will be asked to complete the Vineland Adaptive Behavior Scales, the Communication and Symbolic Behavior Scales (CSBS) and the MacArthur Communicative Development Inventory. In the case that the subjects are recruited from the Ladders infant sib study, we will use the existing ADI-R and ADOS data because Ladders has authorized the release of this information.
The total time for the laboratory session will be approximately 1 hour. The full battery of tasks will be performed on compliant children. For those children whose attention cannot be maintained for the full battery, the examiner will stop and give breaks as needed. The examiner will go on to the next task or terminate the session if the subject or parent of the subject chooses to do so.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Controls: typically developing children 3mo to 8 years without known language or social disorder and not related to child with autism
Exclusion Criteria
3 Months
8 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CURE Foundation
OTHER
The Commonwealth Fund
OTHER
National Alliance for Autism Research
OTHER
Nancy Lurie Marks Family Foundation
OTHER
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Massachusetts General Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Katherine M. Martien, M.D.
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Martha Herbert, M.D.
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MGH LADDERS Clinic
Lexington, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005-P-000868/3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.